Australasian chronic lymphocytic leukaemia consensus statement: 2026 update
Sean McKeague(Royal Brisbane and Women's Hospital), Mary Ann Anderson(The Royal Melbourne Hospital), Giles Best(Flinders University), Joel Wight(Townsville Hospital), Pietro R Di Ciaccio(Australian National University), Rosemary Harrup(University of Tasmania), Kyle Crassini(Coffs Harbour City Council), Joanna Czerwinski(SA Health), Sumita Ratnasingam(Monash Health), Constantine S. Tam(The Alfred Hospital), Tara Cochrane(Gold Coast Hospital), Monique Menzies Wojtowicz(Macquarie University), Rory Bennett(The Royal Melbourne Hospital), X Badoux(St George Hospital), Dipti Talaulikar(Australian National University), Thomas Lew(Peter MacCallum Cancer Centre), Denise Lee(Austin Hospital), Pasquale L. Fedele(Monash Health), N C Chia(Center for Genomic Science), John F. Seymour(The Royal Melbourne Hospital), Masa Lasica(St Vincent's Hospital Melbourne), Stephen P. Mulligan(Royal North Shore Hospital), Stephen Opat(Monash Health), Gavin Cull(The University of Western Australia), Paula Marlton(Princess Alexandra Hospital), Robert Weinkove(Malaghan Institute of Medical Research), Sharon Jackson(Middlemore Hospital), Bryone J. Kuss(Flinders Medical Centre)
Cited by 0
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k